Incretin Effect: What It Is & Why GLP-1 Drugs Work | telos rx
Colorful healthy meal bowl with greens, eggs and vegetables, illustrating the incretin effect and gut hormones
← Back to blog
DPP-4 inhibitors

Incretin Effect: What It Is and How GLP-1 Drugs Use It

By TelosRX Editorial Team

The incretin effect is your gut's insulin boost: eating glucose triggers two to three times more insulin than the same glucose given by IV. Two gut hormones, GIP and GLP-1, drive it. TelosRX explains why it matters for GLP-1 drugs.

Here's a strange fact about your body. Sugar you swallow gets a bigger insulin response than sugar dripped straight into a vein. Same glucose, same blood level, very different reaction.

That gap is the incretin effect. It explains how your gut "talks" to your pancreas. It's also the reason semaglutide and tirzepatide exist at all.

What Is the Incretin Effect?

The incretin effect is the extra insulin your pancreas releases when glucose arrives through the gut. Researchers measure it by comparing an oral glucose drink with an IV infusion matched to the same blood sugar level.

According to a major review, oral glucose produces a two- to three-fold higher insulin response than IV glucose (Nauck & Meier, 2018). The difference comes from hormones released by the gut lining after you eat.

Those hormones are called incretins. The name is a mash-up of "intestine," "secretion," and "insulin." Scientists aren't always poets.

Meet the Two Incretin Hormones: GIP and GLP-1

Two hormones do nearly all the work. They come from different parts of your gut and behave a little differently.

  • GIP (glucose-dependent insulinotropic polypeptide) is made by K cells in the upper small intestine.
  • GLP-1 (glucagon-like peptide-1) is made by L cells, mostly in the lower gut.

Both are released within minutes of a meal. Both tell the pancreas to release more insulin, but only while blood sugar is elevated.

GIP vs GLP-1 at a Glance

Feature GIP GLP-1
Where it's made K cells, upper small intestine L cells, lower small intestine and colon
Effect on insulin Raises insulin when glucose is high Raises insulin when glucose is high
Effect on glucagon Can raise glucagon, especially at low glucose Lowers glucagon when glucose is high
Effect on stomach emptying Minimal Slows it down
Effect on appetite Under active study Reduces appetite and food intake
Response in type 2 diabetes Insulin effect largely blunted Insulin effect preserved at drug-level doses
Drugs built on it Tirzepatide (dual GIP/GLP-1) Semaglutide, liraglutide, tirzepatide

For a deeper look at how these hormones interact with a third player, see our guide to glucagon, GIP, and GLP-1.

How the Incretin Effect Works, Step by Step

The process takes minutes. Here's the short version of what happens after a meal.

  1. Food reaches the small intestine. Glucose, fat, and protein touch the gut lining.
  2. K and L cells sense nutrients. They release GIP and GLP-1 into the bloodstream.
  3. Hormones reach the pancreas. They bind receptors on insulin-making beta cells.
  4. Insulin release is amplified. Beta cells respond more strongly to the same glucose level.
  5. The enzyme DPP-4 breaks them down. Natural GLP-1 lasts only a couple of minutes in the blood.

That last step matters a lot. Native GLP-1 is cleared so fast that it's useless as a drug on its own (Holst, 2007). Drug makers had to engineer longer-lasting versions.

Why the Effect Is "Glucose-Dependent"

Incretins only boost insulin when blood sugar is already up. When glucose falls back toward normal, the insulin push fades.

This is a built-in safety brake. It's one reason GLP-1 receptor agonists used alone carry a lower risk of low blood sugar than some older diabetes drugs. Risk rises when they're combined with insulin or sulfonylureas.

How Big Is the Incretin Effect?

A classic 1986 study measured it directly. In healthy people, incretin factors made up about 73% of the insulin response to oral glucose (Nauck et al., 1986). In people with type 2 diabetes, that share dropped to about 36%.

Put simply, most of your mealtime insulin depends on gut signals. Glucose alone isn't the whole story.

A Short History of the Incretin Effect

The idea is older than you might guess. Early 1900s physiologists suspected the gut sent a signal that lowered blood sugar. They just couldn't find it.

The word "incretin" was coined in the 1930s. The tools caught up in the 1960s. Once insulin could be measured in blood, researchers saw the oral-versus-IV gap clearly.

  • 1970s: GIP was identified as the first incretin hormone.
  • 1980s: GLP-1 was discovered and shown to raise insulin.
  • 1986: The reduced incretin effect in type 2 diabetes was documented.
  • 2005: Exenatide became the first FDA-approved GLP-1 receptor agonist.
  • 2022: Tirzepatide brought dual GIP/GLP-1 action to brand-name prescriptions.

Exenatide has an odd origin story. It's based on a peptide found in Gila monster saliva. Nature had already built a DPP-4-resistant GLP-1 look-alike.

Incretins vs Other Gut Hormones

Your gut makes more than two hormones. Several others shape hunger and digestion. Only GIP and GLP-1 meet the strict incretin definition, though.

  • Peptide YY (PYY): Released with GLP-1 from L cells. It signals fullness.
  • Cholecystokinin (CCK): Released after fat and protein. It slows digestion and helps you feel full.
  • Ghrelin: Made mostly in the stomach. It rises before meals and drives hunger.
  • Amylin: Made in the pancreas alongside insulin. It slows stomach emptying and reduces appetite.

Researchers are now pairing these signals with GLP-1 in experimental drugs. Amylin combinations are one of the most active areas.

Why Incretins Matter for Appetite, Not Just Blood Sugar

The incretin story started with insulin. It didn't end there. GLP-1 receptors sit in the brain, the stomach, the heart, and other tissues.

In the brain, GLP-1 signaling affects areas that control hunger and fullness. In the stomach, it slows how fast food moves on. Together, that means people often feel full sooner and stay full longer.

The same review notes that reduced appetite and food intake lead to weight loss over time (Nauck & Meier, 2018). That's why a "diabetes hormone" became central to weight management.

What Happens to the Incretin Effect in Type 2 Diabetes?

In type 2 diabetes, the incretin effect is reduced or lost. Researchers think two things drive this.

  • GIP stops working well. The pancreas becomes far less responsive to it.
  • GLP-1 still works, but needs a push. At higher-than-natural levels, GLP-1 still raises insulin and lowers glucagon.

That second point opened the door to modern therapy. If natural GLP-1 isn't enough, give a stronger, longer-lasting version (Nauck & Meier, 2018).

The Incretin Effect and Obesity

The same review notes that GLP-1 secretion from the gut seems impaired in people with obesity. That may play a role in how weight gain and blood sugar problems develop together.

It may also help explain changes after gastric bypass surgery. Rerouting food sends nutrients to the lower gut faster, where L cells live. GLP-1 levels rise, alongside other gut hormones like peptide YY.

From Gut Hormone to Medication: Incretin-Based Drugs

Every incretin-based drug works by copying, protecting, or combining these hormones. There are three main families.

GLP-1 Receptor Agonists

These are engineered GLP-1 look-alikes that resist DPP-4 breakdown. Semaglutide is the best-known example. Brand-name Ozempic and Wegovy are FDA-approved for specific indications, including type 2 diabetes and chronic weight management.

Beyond insulin, these drugs slow stomach emptying and reduce appetite. Our article on GLP-1 and gastric emptying covers that piece.

Dual GIP/GLP-1 Agonists

Tirzepatide activates both incretin receptors in one molecule. Brand-name Mounjaro and Zepbound are FDA-approved for specific indications. The dual approach brought GIP back into focus after years of being seen as the "weaker" incretin.

DPP-4 Inhibitors

These oral pills, like sitagliptin, block the enzyme that destroys natural GLP-1 and GIP. Your own incretins last longer. The effect is milder than injectable agonists, and they aren't used for weight loss.

Incretins Beyond the Pancreas: Heart, Fat, and Bone

GIP and GLP-1 were named for their insulin effects. Researchers now know they act on far more tissues. The 2018 review lists fat cells, bone, and the cardiovascular system among them.

The heart findings drew the most attention. In a large outcome trial, liraglutide lowered major cardiovascular events in high-risk adults with type 2 diabetes. Brand-name Victoza now carries that FDA-approved indication.

Effects on fat tissue and bone are still being mapped. GIP receptors on fat cells are one reason scientists revisited GIP for weight management. The bone data is early and mixed.

For you, the takeaway is simple. The incretin system touches more than blood sugar. That's why trials keep measuring heart, kidney, and liver outcomes, not just weight.

What Incretin-Based Drugs Can and Can't Do

Incretin drugs are powerful tools. They aren't magic, and they aren't for everyone. Here's a realistic picture.

  • Common side effects: Nausea, vomiting, diarrhea, and constipation, especially during dose increases.
  • Labeled warnings: Brand GLP-1 drugs carry warnings about pancreatitis, gallbladder problems, and a thyroid C-cell tumor warning.
  • Who should avoid them: People with a personal or family history of medullary thyroid cancer or MEN 2.
  • What they need: Gradual dose increases, adequate protein, and ongoing provider review.

Results vary widely between people. Diet, activity, sleep, other medications, and genetics all play a part.

Curious whether a GLP-1 medication fits your goals? Explore semaglutide at TelosRX or tirzepatide at TelosRX. Compounded versions are not FDA-approved, and any prescription is subject to medical approval by a licensed provider.

Can You Support Your Natural Incretin Response?

Lifestyle won't mimic a prescription drug. But meal composition does change how much GLP-1 your gut releases. Protein, fiber, and healthy fats are the usual suspects in research.

We cover the practical side in how to increase GLP-1 naturally. Think of it as supporting the system you already have.

Key Takeaways

  • The incretin effect is the extra insulin you make when glucose comes through the gut.
  • GIP and GLP-1 are the two hormones behind it.
  • The effect is glucose-dependent, which acts as a natural safety brake.
  • It's reduced in type 2 diabetes, but GLP-1 still works at higher levels.
  • Semaglutide, tirzepatide, and DPP-4 inhibitors are all built on this biology.

How TelosRX Works

TelosRX is an online-first, asynchronous telehealth service. You complete a secure health intake on your own schedule. A licensed provider reviews your history and goals, usually without a live appointment.

If a GLP-1 medication is appropriate, the provider may prescribe it. If not, they'll explain why.

Frequently Asked Questions

What is the incretin effect in simple terms?

It's the extra insulin your body makes when you eat glucose compared with receiving the same glucose by IV. Gut hormones released after a meal tell your pancreas to respond more strongly. Research shows oral glucose produces a two- to three-fold higher insulin response than IV glucose at the same blood sugar level.

Which hormones cause the incretin effect?

Two gut hormones are responsible. GIP comes from K cells in the upper small intestine. GLP-1 comes from L cells, mostly in the lower gut. Both are released after eating and amplify insulin release while blood sugar is elevated. GLP-1 also slows stomach emptying and reduces appetite.

Why is the incretin effect reduced in type 2 diabetes?

In type 2 diabetes, the pancreas becomes much less responsive to GIP, and natural GLP-1 levels aren't enough to make up the difference. A 1986 study found the incretin share of the insulin response was about 73% in healthy people. In people with type 2 diabetes, it was about 36%.

How do GLP-1 drugs use the incretin effect?

GLP-1 receptor agonists like semaglutide mimic natural GLP-1 but resist breakdown by the enzyme DPP-4, so they last days instead of minutes. Tirzepatide activates both GIP and GLP-1 receptors. Both raise insulin when glucose is high, lower glucagon, slow digestion, and reduce appetite.

What is the difference between GLP-1 agonists and DPP-4 inhibitors?

GLP-1 agonists are injectable or oral drugs that directly activate the GLP-1 receptor at strong, sustained levels. DPP-4 inhibitors are pills that block the enzyme that breaks down your own GLP-1 and GIP. DPP-4 inhibitors have a milder effect on blood sugar and are not associated with meaningful weight loss.

Does the incretin effect cause low blood sugar?

On its own, no. The incretin effect is glucose-dependent, so it boosts insulin only while blood sugar is elevated and fades as levels normalize. That's why GLP-1 drugs used alone carry a relatively low risk of hypoglycemia. The risk increases when they're combined with insulin or sulfonylureas, so your provider will review your other medications.

TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.

Start your private evaluation at TelosRX.

Related research

Compounded medications are compounded, not FDA-approved. Prescriptions are never automatic or guaranteed. TelosRX operates under LegitScript-certified telehealth standards as an online-first, asynchronous telehealth service.

Read more from TelosRX